PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq:

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Con

Wolfe Research analyst Rudy Li initiates coverage on Harmony Biosciences Hldgs (NASDAQ:HRMY) with

Aurora Investment Counsel acquired a new position in Harmony Biosciences Holdings, Inc. (NASDAQ: HRM

Harmony Biosciences NASDAQ: HRMY highlighted record quarterly performance for its narcolepsy treatme

California State Teachers Retirement System raised its position in shares of Harmony Biosciences Hol

Healthcare's defensive demand is strengthening in 2026. BTSG, HRMY, UNH and NVCR stand out on improv

Stocks like SNX, AMP, HRMY and NWL are seeing price strength and have a high chance of carrying the

PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq:

Harmony Biosciences (NASDAQ: HRMY) reported second-quarter net revenue of $261.3 million, up 30% fro

Harmony Biosciences Holdings, Inc. has now elevated BP-205, its orexin-2 receptor agonist, to lead t

HRMY tops Q2 estimates as Wakix demand fuels 30% revenue growth. A growing pipeline, BP-205 progress

Truist Securities analyst Danielle Brill maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a

Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.

Harmony Biosciences stock jumped after record Q2 revenue, an earnings beat, strong WAKIX sales and u

Harmony Biosciences Holdings, Inc. (HRMY) Q2 2026 Earnings Call Transcript

Needham analyst Ami Fadia maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and raises

Harmony Biosciences NASDAQ: HRMY reported second-quarter net revenue of $261.3 million, up 30% from

Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $1.28 per share, beati

Harmony Biosciences (NASDAQ:HRMY) reported quarterly earnings of $1.28 per share which beat the anal

Harmony Biosciences Hldgs (NASDAQ:HRMY) affirms FY2026 sales outlook from $1.000 billion-$1.040 bill

WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Aver

Mizuho analyst Graig Suvannavejh maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Outperf

With the Fed holding rates steady and Middle East tensions clouding market sentiment, ARW, PENN, GOO

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and

Harmony Biosciences, Invesco, GM, HPE and Quanex made the screen of low price-to-book stocks that al

Harmony Biosciences (HRMY) is evolving from a single-product firm into a self-funded neuroscience pl

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Harmony Biosciences Hldgs (NASDAQ:

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced preliminary, unaudited second quart

Harmony Biosciences Hldgs (NASDAQ:HRMY) affirms prelim FY2026 sales outlook from $1.000 billion-$1.0

Deutsche Bank analyst David Hoang maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Hold a

Truist Securities analyst Danielle Brill maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a

Harmony Biosciences Hldgs (NASDAQ:HRMY) affirms FY2026 sales outlook from $1.000 billion-$1.040 bill

Harmony Biosciences (NASDAQ:HRMY) reported quarterly earnings of $0.55 per share which missed the an

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the appointment of Glenn Reicin a

Appointments support Harmony's next phase of growth and long‑term value creationHarmony Bioscien

UBS analyst So Youn Shim maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Neutral and low

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Harmony Biosciences Hldgs (NASDAQ:

B of A Securities analyst Jason Gerberry maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a

Needham analyst Ami Fadia maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and lowers

Harmony Biosciences (NASDAQ:HRMY) reported quarterly earnings of $0.57 per share which missed the an

WAKIX was approved by the FDA in August 2019 for the treatment of excessive daytime sleepiness (EDS)